Updated Glioblastoma Data Demonstrated Median OS of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy November 18, 2026
Additional Long-Term Follow-Up Data from Ph 2 Study of Safusidenib in IDH1-Mutant Glioma Presented November 18, 2026
Updated interim results from U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with recurrent GBM announced November 18, 2026
FAILED TRIAL: Ph 2b SURVIVE Trial of SurVaxM in Newly Diagnosed GBM didn’t meet primary endpoint of OS improvement October 14, 2026
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Ph 2a Results September 22, 2026
MT027 Receives FDA IND Clearance to Proceed to Ph 2 clinical Trial for Recurrent GBM September 2, 2026
TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement aimed at Ph 2 development of NOX-A12 August 25, 2026
Enrollment opens in Ph 1 Clinical Trial Evaluating Treatment of Malignant Brain Tumors with APTN-101 August 25, 2026
Positive Topline Ph 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Reported August 20, 2026
Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma to be presented August 11, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 28, 2026
Last Patient, Last Visit in LAM561 Ph 2b/3 Trial for Newly Diagnosed GBM Patients Announced July 28, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 21, 2026
Encouraging Preliminary Data from Ongoing Ph 2 Study of BPM31510 in Newly Diagnosed GBM Reported July 21, 2026
FDA Provides Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition July 21, 2026
FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements July 15, 2026